Traders should monitor late Q2 2026 for topline Phase 3 data from the ABTECT-UC trial, which will be a major catalyst. The strong cash runway into Q4 2027 supports continued development, but profitability remains distant.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 24 $110.17entry
- T+1 · 8mo ago +0.48%α −0.09% · $110.70
- T+5 · 8mo ago +1.07%α +1.49% · $111.35
- T+20 · 7mo ago +5.28%α −3.62% · $115.99
- T+60 · 5mo ago −10.00%α −24.33% · $99.15
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Abivax reported full-year 2025 financial results with a net loss of €336.1 million, driven by higher R&D and G&A expenses, but strengthened its balance sheet with €530.4 million in cash after a $700.3 million public offering. The company remains on track to report topline Phase 3 data for obefazimod in ulcerative colitis in late Q2 2026, and appointed a new Chief Commercial Officer to prepare for potential commercialization.
Key Financial Metrics
Key Facts
- Net loss widened to €336.1 million in 2025 from €176.2 million in 2024
- Cash, cash equivalents, and short-term investments totaled €530.4 million as of December 31, 2025
- Raised $700.3 million (€597.2 million) in a public offering in July 2025
- DSMB found no new safety signals in the Phase 3 ABTECT-UC trial; topline results expected late Q2 2026
- Appointed Michael Nesrallah as Chief Commercial Officer to lead launch preparation for obefazimod
Financial Impact
Cash position increased by €372.5 million net of operations and financing; operating loss increased by €73.1 million year-over-year
Risk Factors
- Clinical trial results may not meet endpoints despite favorable safety data
- High cash burn rate: €161.1 million used in operations in 2025
- Dilution from the $700.3 million public offering may pressure shares if results disappoint
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3260837 |
Track record
10 reports on ABVX
4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +33.05% at T+60 after the Jul 2, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $83.40 Now $87.58 +5.01% settles Nov 24
- Oct 30, 202617d ago Institutional Cluster Neutral 2/10 Entry $86.59 to $85.73 Now $87.58 +1.14% ▼ −0.99% +1.71% vs SPY
- Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $130.00 to $121.45 Now $87.58 −32.63% ▼ −6.58% −7.79% vs SPY
- Jul 2, 202619w ago 6-K Bearish 6/10 Entry $144.65 to $140.74 Now $87.58 +39.45% ▲ +2.70% +3.63% vs SPY
- Jul 2, 202619w ago 424B5 Bearish 6/10 Entry $144.65 to $140.74 Now $87.58 +39.45% ▲ +2.70% +3.63% vs SPY
- Jul 1, 202619w ago Press Release Bearish 6/10 Entry $132.56 to $142.17 Now $87.58 +33.93% ▼ −7.25% −6.99% vs SPY
- Jun 29, 202620w ago 6-K Bullish 7/10 Entry $133.26 to $143.99 Now $87.58 −34.28% ▲ +8.05% +7.45% vs SPY
- Jun 29, 202620w ago Press Release Bullish 7/10 Entry $133.26 to $143.99 Now $87.58 −34.28% ▲ +8.05% +7.45% vs SPY
- May 22, 202625w ago Press Release Neutral 5/10 Entry $126.41 to $129.69 Now $87.58 −30.72% ▲ +2.59% +1.51% vs SPY
- Mar 23, 202634w ago Press Release Mixed 6/10 Viewing Entry $110.17 to $111.35 Now $87.58 −20.50% ▲ +1.07% +1.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers